Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

Opinion
Video

Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.

Video content above is prompted by the following:

  • How strictly do you adhere to the loading dose recommendations for new therapies in treatment-naive patients with neovascular age-related macular degeneration and diabetic macular edema?
  • How about for patients who are switching therapies?
Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
2 experts in this video
Related Content
Two boxes, labeled "yes" and "no." There is a red checkmark in the "no" box. Concept portraying an ophthalmic clinical trial which does not meet its endpoint. Image credit: ©Matthew Benoit – stock.adobe.com

Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports

Martin David Harp
March 24th 2025
Article

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A blue hazard sign, an exclamation point (!) inside a triangle, to communicate the risks of misdiagnosing geographic atrophy and age-related macular degeneration. Image credit: ©jcsnb – stock.adobe.com

Researchers raise awareness of macular pathologies which mimic AMD and GA

Lynda Charters
March 20th 2025
Article

Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An image showing the degeneration of neuron cells. Image credit: ©Corona Borealis – stock.adobe.com

Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD

Jordana Joy
March 3rd 2025
Article

One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

An illustration of kidneys, in black-and-white, with color over some sections to indicate disease. Image credit: ©Crystal light – stock.adobe.com

EMA validates indication extension application of pegcetacoplan for treatment of kidney disease

Hattie Hayes
February 20th 2025
Article

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria

© 2025 MJH Life Sciences

All rights reserved.